As we known, the point mutations in ABL kinase domain were responsible for TKIs resistance in CML patients [76], with this reason considered, we constructed ZFNs targeting BCR domain which also made the ZFNs suitable for treating drug-resistant patients with different mutations. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.